1,495 results on '"Ringdén, O"'
Search Results
2. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?
3. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies
4. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages
5. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy
6. Stromal cells–are they really useful for GVHD?
7. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice
8. Bone Marrow Transplantation Using Related Donors
9. Liposomales Amphotericin B (Ambisome®): Erste Ergebnisse zur Behandlung lebensbedrohlicher, systemischer Mykosen
10. Bone marrow aspiration technique has deteriorated in recent years
11. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
12. Superselective intra-arterial umbilical cord blood administration to BM in experimental animals
13. Effects of spleen status on early outcomes after hematopoietic cell transplantation
14. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma
15. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation
16. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
17. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia
18. No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells
19. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT
20. Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection
21. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism
22. DECREASED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE USING REDUCED INTENSITY CONDITIONING COMPARED TO MYELOABLATIVE CONDITIONING IS INDEPENDENT OF DONOR-RECIPIENT T-CELL CHIMERISM: PH-AB230
23. HOME-CARE DURING NEUTROPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS IS SAFE AND MAY BE ADVANTAGEOUS TO ISOLATION IN THE HOSPITAL: PH-P551
24. 30 YEARS OF EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM: PH-P457
25. THIRTY YEARSʼ EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR GAUCHER DISEASE IN SWEDEN: PH-P451
26. DECIDUAL STROMAL CELL THERAPY MAY INDUCE MULTISPECIFIC ANTI-HLA ANTIBODIES IN EPIDERMOLYSIS BULLOSA PATIENTS, BUT NOT IN ALLOGENEIC SCT PATIENTS: PH-P066
27. LONG-TERM FOLLOW UP OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS TREATMENT FOR SOLID TUMORS: PH-O122
28. Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor
29. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis
30. No impact of NOD2/CARD15 on outcome after SCT
31. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation
32. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen
33. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival
34. Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study
35. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
36. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
37. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
38. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
39. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases
40. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
41. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation
42. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease
43. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
44. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation
45. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation
46. Viridans streptococcal septicaemia in neutropenic patients: role of proinflammatory cytokines
47. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation
48. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
49. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV
50. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.